DRKS00011420招募中未知
Study on intensified follow-up care for malign neoplasma of the mammary gland under self-anamnesis - SiNaB
St. Joseph-Stift Bremen0 个研究点目标入组 200 人开始时间: 2016年12月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 30 Years 至 50 Years（—）
- 性别
- Female
入选标准
- •Female insured members of the AOK Bremen / Bremerhaven at the age of 30 - 50 years
- •Diagnosis according to ICD-10-GM 2016: C 50.0 - 9 Malignant neoplasm of the mammary gland or Z85.3 Malignant neoplasm of the mammary gland in its own anamnesis
- •Disease already in remission
- •Written consent to participate in the study (informed consent)
排除标准
- •Mastectomy (OPS 5-870, 5-874, 5-877, 5-872)
- •Existing pregnancy
- •Contrast agent allergy
- •Overactive thyroid
- •planned change of residence within the intervention period
- •Absolute and relative contraindications against magnetic resonance tomography of the breast (eg iron-containing material in the body, heart pacemaker)
研究者
相似试验
尚未招募
Unknown
Intensified aftercare preparation for oncological rehab patients: Development and evaluation of a sequential blended learning concept for rehabilitation and aftercare.C50C81-C96D05C51-C58Malignant neoplasm of breastMalignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissueCarcinoma in situ of breastMalignant neoplasms of female genital organsDRKS00033277IfR, Norderney, Abt. Bad Salzuflen364
尚未招募
不适用
Retrospective study of postoperative management of robot-assisted rectal resection performed at our hospitalJPRN-UMIN000035017Department of anesthesiolgy, Sapporo medical university school of medicine40
进行中（未招募）
2 期
Phase II study of intensive treatment for newly diagnosed elderly acute myeloid leukemia, fitted for standard chemotherapy like younger adults, by Japan Adult Leukemia Study Group (JALSG-GML219)acute myeloid leukemiaJPRN-jRCTs041190088Ito Yoshikazu128
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
进行中（未招募）
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-002440-40-DESangamo Therapeutics France SAS15